Janux Therapeutics to Participate in Novel IO Panel Discussion at Cowen's 43rd Annual Health Care Conference

Rhea-AI Summary

Janux Therapeutics, Inc. (Nasdaq: JANX) announced its participation in a Novel Immuno-Oncology panel discussion at Cowen's 43rd Annual Health Care Conference in Boston from March 6 to 8, 2023. Janux will present on March 6 from 9:10 AM to 10:10 AM ET. The company specializes in developing innovative immunotherapies using its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms. Its focus includes creating T cell engagers targeting PSMA, EGFR, and TROP2, while also enhancing anti-tumor activity through additional bispecific product candidates. Archived presentations will be accessible on Janux's website for 90 days.

SAN DIEGO--(BUSINESS WIRE)-- Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced that Janux management will participate in a Novel Immuno-Oncology (IO) panel discussion at Cowen's 43rd Annual Health Care Conference and be available for 1x1 meetings from March 6 to 8, 2023 in Boston. Details of the presentations are as follows:

Cowen's 43rd Annual Health Care Conference
Date: Monday, March 6
Time: 9:10am to 10:10am Eastern Time
Location: Boston Marriott Copley Place
Forum: Novel IO Panel

Presentations and subsequent archived replay may be accessed via the Investors & Media section of Janux’s website. An archived replay of the webcast will be available on the website for approximately 90 days following the presentation.

About Janux Therapeutics

Janux Therapeutics is an innovative clinical-stage biopharmaceutical company developing next-generation therapeutics based on applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms to better treat patients suffering from cancer. Janux’s initial focus is on developing a novel class of T cell engagers (TCEs), and its lead product candidates are designed to target clinically validated drug targets. While TCE therapeutics have displayed potent anti-tumor activity in hematological cancers, developing TCEs to treat solid tumors have faced challenges due to the limitations of prior TCE technologies, namely (i) overactivation of the immune system leading to cytokine release syndrome, (ii) on-target, healthy tissue toxicities, and (iii) poor pharmacokinetics leading to short half-life. Janux is using its TRACTr platform technology to engineer product candidates designed to overcome these limitations by offering accuracy, stability, activity, modularity, and manufacturability. Janux is developing a broad pipeline with lead TRACTr programs targeting prostate-specific membrane antigen (PSMA), epidermal growth factor receptor (EGFR), and trophoblast cell surface antigen 2 (TROP2). Janux is also applying its proprietary technology to develop a TRACIr costimulatory bispecific product candidate against programmed death-ligand 1 (PD-L1) and Cluster of Differentiation 28 (CD28) designed to further enhance the anti-tumor activity of T cells. For more information, please visit www.januxrx.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230214005399/en/

Investors:

Andy Meyer

Janux Therapeutics

ameyer@januxrx.com

(202) 215-2579

Media:

Jessica Yingling, Ph.D.

Little Dog Communications Inc.

jessica@litldog.com

(858) 344-8091

Source: Janux Therapeutics, Inc.

FAQ

When is Janux Therapeutics participating in the Cowen Health Care Conference?

Janux Therapeutics will participate in the Cowen's 43rd Annual Health Care Conference from March 6 to 8, 2023.

What time will Janux present at the Cowen Health Care Conference?

Janux will present on March 6, 2023, from 9:10 AM to 10:10 AM Eastern Time.

What platforms does Janux Therapeutics utilize for immunotherapy development?

Janux utilizes its proprietary Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms for immunotherapy development.

What are the lead product candidates of Janux Therapeutics?

Janux's lead product candidates target prostate-specific membrane antigen (PSMA), epidermal growth factor receptor (EGFR), and trophoblast cell surface antigen 2 (TROP2).

Where can I find the archived presentation of Janux at the conference?

The archived presentation will be available on Janux's website for approximately 90 days after the conference.